- Conditions
- Crohn's Disease
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 33
- States / cities
- Dothan, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 97
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Crohn Disease
- Interventions
- Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg, Placebo SC, Placebo IV
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 50
- States / cities
- Scottsdale, Arizona • Anaheim, California • Sacramento, California + 47 more
- Conditions
- Crohn Disease
- Interventions
- Risankizumab 600 mg IV, Risankizumab 180 mg SC
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Chevy Chase, Maryland • Chesterfield, Michigan
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab pegol, Azathioprine
- Biological · Drug
- Lead sponsor
- Gastroenterology Research of America
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Crohn Disease
- Interventions
- VTX958, VTX958 Placebo
- Drug
- Lead sponsor
- Ventyx Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 26
- States / cities
- Garden Grove, California • Lancaster, California • Kissimmee, Florida + 21 more
- Conditions
- Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
- Interventions
- Vedolizumab
- Biological
- Lead sponsor
- Alimentiv Inc.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Charleston, South Carolina • Houston, Texas
- Conditions
- Ulcerative Colitis, Crohn's Disease
- Interventions
- Vedolizumab IV, Vedolizumab SC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more
- Conditions
- Moderately to Severely Active Crohns Disease
- Interventions
- Afimkibart, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 95
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 79 more
- Conditions
- Crohn's Disease
- Interventions
- IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
- Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 87
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
- Conditions
- Crohn's Disease, IBD
- Interventions
- Brazikumab low dose, Brazikumab high dose, Humira®, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more
- Conditions
- Crohn Disease
- Interventions
- Ozanimod, Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 188
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 140 more
- Conditions
- Crohn's Disease
- Interventions
- Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 12
- States / cities
- Oakland, California • Palo Alto, California • Aurora, Colorado + 9 more
- Conditions
- Crohn Disease
- Interventions
- Ozanimod
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 854 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 190
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more
- Conditions
- Crohn Disease
- Interventions
- RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
- Drug
- Lead sponsor
- RedHill Biopharma Limited
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- San Carlos, California • Marietta, Georgia • Topeka, Kansas + 3 more
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease
- Interventions
- Placebo, MORF-057
- Drug
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 25
- States / cities
- Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more
- Conditions
- Crohn Disease
- Interventions
- JNJ-67864238, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Colorado Springs, Colorado • Clearwater, Florida • Macon, Georgia + 10 more
- Conditions
- Crohn's Disease
- Interventions
- Placebo (IP), Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP), Placebo IV - Responder - Placebo SC (MP), Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP), Ustekinumab IV - Responder - Placebo SC (MP), Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP), Ustekinumab IV - Nonresponder - Placebo SC (MP), Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 88
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more
- Conditions
- Crohn's Disease
- Interventions
- Placebo, ABT-874
- Biological
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 36
- States / cities
- Orange, California • San Diego, California • Hamden, Connecticut + 30 more
- Conditions
- Crohn Disease
- Interventions
- Tulisokibart, Companion Diagnostic (CDx)
- Biological · Diagnostic Test
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Liberty, Kansas • Chesterfield, Michigan + 11 more
- Conditions
- Colitis, Ulcerative, Crohn Disease
- Interventions
- Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Cypress, California • Miami, Florida
- Conditions
- Crohn Disease
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 77
- States / cities
- Dothan, Alabama • Chandler, Arizona • Scottsdale, Arizona + 65 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab, Golimumab, JNJ-78934804, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
- Conditions
- Crohn's Disease
- Interventions
- ABBV-154, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 45
- States / cities
- Dothan, Alabama • Mobile, Alabama • Coronado, California + 38 more
- Conditions
- Crohn's Disease
- Interventions
- Trichuris suis ova (TSO), Placebo
- Biological
- Lead sponsor
- Coronado Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 73
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 64 more